|
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
Number of employees : 1 541 people.
|
|
| 2020 | 2021 | Delta | Recombinant Vaccines | 475.60 | 100% | 1 146.29 | 100% | +141.02% |
USD in Million |
|
|
| 2020 | 2021 | Delta | United States | 475.60 | 100% | 1 146.29 | 100% | +141.02% |
USD in Million |
|
|
Name |
Title |
Age |
Since |
John C.s Jacobs |
President, Chief Executive Officer & Director |
55 |
2023 |
James Kelly |
Chief Financial Officer, Treasurer & Executive VP |
56 |
2021 |
Gregory Glenn |
President-Research & Development |
68 |
2016 |
Biegie Lee |
Chief Information Officer & Senior Vice President |
- |
2020 |
Gale Smith |
Vice President-Vaccine Development |
- |
2004 |
Filip Dubovsky |
Chief Medical Officer & Executive Vice President |
- |
2020 |
Raburn Mallory |
Senior Vice President & Head-Clinical Development |
- |
2021 |
Seth Toback |
Senior Vice President-Medical Affairs |
- |
2020 |
Richard Crowley |
Chief Operating Officer & Executive Vice President |
65 |
2020 |
Troy Morgan |
Chief Compliance Officer & Senior Vice President |
- |
2021 |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
79,231,647 |
78,140,997 |
98.6% |
727,695 |
0.9% |
98.6% |
|
|
Name | Equities | % | The Vanguard Group, Inc. | 7,992,228 |
9.40% | SSgA Funds Management, Inc. | 3,655,428 |
4.30% | BlackRock Fund Advisors | 1,878,454 |
2.21% | Citigroup Global Markets, Inc. (Investment Management) | 1,358,275 |
1.60% | Voloridge Investment Management LLC | 1,333,706 |
1.57% | Perceptive Advisors LLC | 1,043,000 |
1.23% | Geode Capital Management LLC | 1,041,232 |
1.22% | Renaissance Technologies LLC | 880,583 |
1.04% | Goldman Sachs & Co. LLC (Private Banking) | 878,989 |
1.03% | Credit Suisse International (Investment Management) | 868,229 |
1.02% |
|
|
|
|
Novavax cuts full-year revenue forecast |
Sector Other Biotechnology & Medical Research
| | 1st jan. | Capi. (M$) |
 | NOVAVAX, INC. | 9.82% | 971 |
| | | |
 | MODERNA, INC. | 5.42% | 72 745 |
 | LONZA GROUP AG | 17.24% | 42 787 |
 | IQVIA HOLDINGS INC. | 12.00% | 42 622 |
 | ALNYLAM PHARMACEUTICALS, INC. | -2.64% | 28 465 |
 | SEAGEN INC. | 9.46% | 26 117 |
 | CELLTRION, INC. | 3.93% | 19 410 |
 | ICON PUBLIC LIMITED COMPANY | 17.50% | 18 635 |
 | HANGZHOU TIGERMED CONSULTING CO., LTD. | 17.73% | 15 274 |
 | PHARMARON BEIJING CO., LTD. | 21.62% | 13 857 |
 | BIO-TECHNE CORPORATION | -2.04% | 12 744 |
 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 12.48% | 12 470 |
 | UNITED THERAPEUTICS CORPORATION | -6.62% | 11 835 |
 | QIAGEN N.V. | -1.14% | 11 226 |
 | GENSCRIPT BIOTECH CORPORATION | 18.11% | 7 929 |
 | MEDPACE HOLDINGS, INC. | 5.31% | 6 938 |
 | BACHEM HOLDING AG | 3.88% | 6 642 |
 | ROIVANT SCIENCES LTD. | 7.01% | 6 202 |
 | IONIS PHARMACEUTICALS, INC. | 5.96% | 5 685 |
 | PROMETHEUS BIOSCIENCES, INC. | 5.56% | 5 398 |
 | JOINN LABORATORIES(CHINA)CO.,LTD. | 13.73% | 4 913 |
Connections : Novavax, Inc.
|